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ibrosis
Living Tissue
nd the Infarcted Heart*
arl T. Weber, MD, FACC,†
ao Sun, MD, PHD,† Javier Dı´ez, MD, PHD‡
emphis, Tennessee; and Pamplona, Spain
eart failure has reached epidemic proportions among the
lderly, in whom it is most often attributable to an ischemic
ardiomyopathy (ICM) with previous myocardial infarc-
ion(s) (MIs). The infarcted heart is a “house divided” (1),
ts myocardium disrupted by the loss of necrotic cardiomyo-
ytes, its structural syncytium interrupted by an infarct scar,
nd its remaining viable myocardium corrupted by an
nterstitial fibrosis. Multiple foci of replacement fibrosis, in
ombination with interstitial fibrosis, are reported to be the
ajor cause of ventricular remodeling in the cardiomyo-
athic heart of ischemic origin, where it accounts for nearly
0% of fibrotic tissue; infarction (scar) comprises 30% (2).
See page 2017
The electrical behavior of the infarcted heart and its function
uring systolic and/or diastolic phases of the cardiac cycle are
ach perturbed by the accumulation of fibrous tissue (3). An
nderstanding of the pathobiology responsible for the fibrosis
hat appears remote to the infarct could forge new frontiers in
dentifying risk for such adverse structural remodeling and in so
oing, prevent the onset of heart failure and thwart its progressive
ature. What is known about fibrosis in the infarcted heart?
ollagen turnover after MI. Cleutjens et al. (4) studied
he timeline of collagen degradation and synthesis in the
nfarcted rat heart. During the early days after left coronary
rtery ligation, the activity and expression of matrix metal-
oproteinases rose at the infarct site, only to be attenuated by
ay 7 with the up-regulation of their tissue inhibitors.
hereafter, collagen synthesis prevailed. Increased messen-
er ribonucleic acid expression of type I and III fibrillar
ollagens appears predominantly at, and to a lesser extent,
emote to the infarcted left ventricle (LV), which includes
he noninfarcted interventricular septum and right ventricle
RV) and where it was persistent for prolonged periods.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Division of Cardiovascular Diseases, University of Tennessee HealthM
cience Center, Memphis, Tennessee; and the ‡Division of Cardiovascular Sciences,
entre of Applied Medical Research, University of Navarra, Pamplona, Spain.ells responsible for fibrous tissue. Phenotypically trans-
ormed fibroblast-like cells, termed myofibroblasts because
hey express alpha-smooth muscle actin (SMA) microfila-
ents, express fibrillar collagens found at and remote to the
nfarct (5). The myofibroblasts arrive at the infarct site on days
and 4 post-MI and remain there for prolonged periods (months
n rats and years in humans). Their ongoing activity creates a
living tissue” that imparts a dynamic nature to collagen turnover.
e novo angiotensin (Ang)II generation in the regula-
ion of myofibroblasts collagen turnover. Various imag-
ng techniques have been used to monitor the cellular and
olecular biology involved in angiotensin peptide (AT)
eneration in the infarcted rat heart (5). Increased expres-
ion of angiotensinogen and renin, together with renin
ctivity, and high-density angiotensin-converting enzyme
ACE) and AT1 receptor radioligand binding are found on
ay 7 post-MI and localized to both macrophages and
yofibroblasts. A progressive rise in ACE and AngII
eceptor binding densities are found at the infarct site at 2,
, and 8 weeks after MI and are associated with myofibro-
lasts; macrophages gradually disappear beyond day 14. At
eek 2 and beyond, increased ACE and AngII receptor
inding densities are also found remote to the MI and other
ites of fibrous tissue accumulation, such as pericardial
brosis. The ACE and AngII receptor binding at 4 weeks
ost-MI are shown in Figure 1. Displacement studies, using
T1 and AT2 receptor antagonists, identified AT1 receptors
o be the predominant subtype. Increased expressions of
ransforming growth factor (TGF)-1 and type I collagen
ere likewise found at the infarct site and attributed to
yofibroblasts. In an auto/paracrine manner, myofibro-
last-based AngII generation up-regulates the expression of
he fibrogenic cytokine TGF-1 during tissue repair, with
GF-1 responsible for myoFb collagen synthesis. Treat-
ent with an ACE inhibitor or AT1 receptor antagonist
ttenuates the expression of TGF-1, type I collagen, and
he appearance of fibrous tissue found at the various sites of
ealing, including the noninfarcted LV and RV (4,5).
Thus, tissue repair involving myofibroblasts and their de
ovo generation of AngII and TGF-1 serve to regulate
ollagen turnover at and remote to MI and to account for
brous tissue formation. Fibrosis is a dynamic living tissue
hose activity can be modified by an ACE inhibitor or AT1
eceptor antagonist.
onitoring fibrosis in the infarcted heart. Interstitial
brosis remote to the infarct is an important determinant of
bnormal electrical and mechanical behavior of the infarcted
eart. The approach to monitoring fibrosis might proceed
long different yet complementary directions.
yofibroblasts. In this issue of the Journal, van den Borne
t al. (6) have addressed the utility of intravenous techne-
ium 99m (99mTc)–labeled Cy5.5-RGD imaging peptide
CRIP), together with single-photon emission computed
omography, in monitoring myofibroblasts at and remote toI in the open-chested mouse after left coronary artery
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Fibrosis: Living Tissue December 9, 2008:2029–31igation. The peptide binds to integrins, adhesion molecules
xpressed by these myofibroblasts as they attach to fibrillar
ollagen at the site of repair. Fluorescence microscopy identi-
ed probe uptake to localize with alpha-SMA–positive myo-
broblasts, whose ultrastructure was confirmed by immuno-
lectron microscopy, and paralleled collagen fibrillogenesis. It
as at its maximum at week 2 post-MI and remained increased
t 4 and 12 weeks, with a time course similar to that in
nhanced tissue labeling seen at sites remote to the MI. The
RIP uptake at 4 weeks post-MI was attenuated by captopril
lone or in combination with losartan. This is a promising
pproach. The study was conducted in the infarcted mouse
eart where, unlike in the rat, collagen expression and
ccumulation at the infarct site is low, thereby raising the
ropensity for rupture, which is even lower remote to the
I. Wound healing post-MI in mice is more rapid and
ssociated with a disappearance of myofibroblasts compared
ith rats and humans, where they are more persistent.
dditionally, a number of cells participating in tissue repair,
ncluding myofibroblasts and inflammatory and endothelial
ells, have an up-regulated expression of adhesion molecules
Figure 1 Angiotensin-Converting Enzyme and Angiotensin II Re
Quantitative in vitro autoradiographic imaging of angiotensin-converting enzyme (AC
heart, revealing the right ventricle (RV) and left ventricle (LV). Binding densities are
sity binding. [125I]351A, a tyrosyl derivative of lisinopril, was used to monitor ACE
myocardial infarction (MI) (B), binding density has increased throughout the heart,
pericardial (PF) and endocardial fibrosis (EF) evident by histochemical staining and
used to monitor AngII receptor binding. In the control rat heart (C), AngII binding d
remote sites that include pericardial and endocardial fibrosis. Displacement studie
receptors as the predominant subtype in the infarcted rat heart (not shown).hat could make CRIP binding less specific for myofibro- alasts. Tissue binding of this radionuclide does not directly
onitor myofibroblast activity or their turnover of collagen.
onitoring ACE and AngII receptors. As noted above,
adiolabeled ACE inhibitors, together with quantitative in
itro autoradiography, have identified increased ACE binding
n the infarcted rodent and human heart, particularly at the site
f infarction, while AngII receptors have been detected using
adiolabeled Ang receptor blockers (5,7,8). Intravenous 99mTc-
abeled losartan was used in a murine model of MI in which,
t 1 to 6 weeks after coronary artery ligation, dense uptake was
bserved at the infarct site (8). To date, no reports have
ppeared on the use of these tracers in humans.
erologic markers of collagen turnover. Monitoring var-
ous peptides, derived from the synthesis and degradation of
ype I and type III collagens, holds promise as a noninvasive
ool regarding the extent of myocardial fibrosis and its
athobiology, as well as patient prognosis and response to
herapy. The accumulating evidence, mainly obtained in
atients with hypertensive heart disease, points to the
arboxy-terminal propeptide of procollagen type I (PICP) as
he only circulating molecule that meets the criteria required
r Binding
angiotensin (Ang)II receptor binding densities in coronal sections of the rat
-coded: red and yellow indicate the highest density and purple the lowest den-
g density. In the control rat heart (A), ACE binding density is low; at week 4 after
he highest density seen at the infarct (MI) and sites remote to it, which include
icroscopy (not shown). 125I[Sar1,Ile8]AngII, an Ang receptor antagonist, was
is low; at week 4 post-MI (D), high-density binding is found at the infarct and
g angiotensin peptide (AT)1- and AT2-specific receptor antagonists identified AT1cepto
E) and
color
bindin
with t
light m
ensity
s usins a true biochemical marker of myocardial fibrosis (9).
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December 9, 2008:2029–31 Fibrosis: Living TissueICP is cleaved from procollagen type I during the extra-
ellular synthesis of fibril-forming collagen type I.
Increased serum concentrations of PICP have been reported
n patients within the first days after MI (10–12). When
atients were stratified according to PICP values at presenta-
ion or at 3 months post-infarction, those presenting with the
ighest values developed progressive LV dilatation, reduced
jection fraction, and impaired diastolic filling (10–12). In
ddition, change in serum PICP proved to be an independent
redictor of cardiac death or heart failure during follow-up
12). Therefore, serum PICP concentration is related to the
evelopment of LV remodeling and dysfunction after MI, and
rovides prognostic information.
In summary, fibrosis appears at and remote to MI. At
emote sites, it represents the major component to the
dverse structural remodeling in the failing heart of ischemic
rigin. Fibrosis is a living tissue. It includes a population of
yofibroblasts whose ongoing collagen turnover is related
o their de novo generation of AngII and its auto/paracrine
egulation of TGF-1. By examining tissue repair after MI,
ncluding the pathobiology and dynamic nature of cardiac
brosis, novel insights into predicting the risk of such
dverse structural and geometric remodeling, preventing the
nset of ventricular dysfunction, and interfering with the
rogressive nature of heart failure can be gained.
eprint requests and correspondence: Dr. Karl T. Weber,
ivision of Cardiovascular Diseases, University of Tennessee
ealth Science Center, 920 Madison Avenue, Suite 300, Mem-his, Tennessee 38163. E-mail: KTWeber@utmem.edu.
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